BioProcess Algae dealed with KD-Pharma for EPA-rich omega-3 oils
date:Jul 04, 2012
n these players are difficult as each have different microalgae strains, different technologies and different end products.

Unusual manufacturing process a USP in the algal omega market

CEO Tim Burns added: Our strategy is to continue to expand our co-location operations by growing high-quality feedstock at attractive prices.

We intend to integrate additional off-takes to increase our operational efficiency, continue to gain economies of scale and to enhance profitability, and this agreement
3/8 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
05/03 03:04